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Combination toxicity of etoposide (VP-16) and photosensitisation with a
water-soluble aluminium phthalocyanine in K562 human leukaemic cells
TG Gantchev, N Brasseur and JE van Lier
Department ofNuclear Medicine and Radiobiology, Faculty ofMedicine, University ofSherbrooke, Sherbrooke, QC, JIH 5N4,
Canada.
Summary Etoposide (VP-16) is an anti-cancer drug commonly used against several types of tumours and
leukaemia, either alone or in combination chemotherapy. Photodynamic therapy (PDT) is another, relatively
new modality for treatment of various malignancies. The interactions between VP-16 and PDT, using
aluminium tetrasulphophthalocyanine as photosensitiser, in K562 human leukaemic cells were investigated. Cell
responses to individual and combined drug treatment under different experimental conditions revealed
synergistic drug toxicity. The latter was evident from various events of cell response, including supra-additive
accumulation of cells in G2/M cell cycle phase and endonucleolytic DNA fragmentation (apoptosis). The
involvement of the cellular antioxidant system in the synergistic interactions of photosensitisation and VP-16 is
proposed.
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Etoposide[4'-dimethylepipodophyllotoxin-9-(4,6-O-ethylidene-
fl-D-glucopyranoside, VP-16] is an important antineoplastic
agent used against several tumour types, either alone (Issel et
al., 1984), or in combination therapy (Aisner and Lee, 1991).
Etoposide is also commonly used for the treatment of acute
myelogenous leukaemia (Champlin and Gale, 1987). The
cytotoxicity of VP-16 is generally believed to be based on
introduction of DNA damage by drug interference with
breakage -reunion reaction of DNA-topoisomerase II
(formation of DNA-protein cross-links) (Glisson and Ross,
1987; Liu, 1989) and/or induction of direct DNA strand
breaks and adducts (van Maanen et al., 1988a, b; Mans et al.,
1991). In contrast to the topoisomerase II (topo II) poisoning
by VP-16 itself, the direct inactivation of DNA was suggested
to be conjugated with oxidation-reduction activation of VP-
16 in the cellular environment (Mans et al., 1990, 1992). In
particular, cytochrome P450-dependent mono-oxygenases,
peroxidases, prostaglandin synthetase, tyrosinase, etc. may
be involved in VP-16 metabolic transformation (van Maanen
et al., 1987; Haim et al., 1991; Gantchev et al., 1994a).
Evidence has been found that peroxidative metabolic
products of VP-16, e.g. the ortho-quinone derivative of
etoposide, as well as the short-lived intermediates (phenoxyl
and semi-quinone free radicals) are involved in various
oxidative reactions and DNA damage (Mans et al., 1990,
1991; Sinha et al., 1990). Recent studies suggest that the
interactions of VP-16 free radicals with intracellular
reductants (thiols, ascorbic acid, etc.) might play an essential
role in the cytotoxic activity of the drug as well (Mans et al.,
1992; Kagan et al., 1994; Yokomizo et al., 1995).
Light activation of photosensitisers that have been
accumulated in tumours is the basis of the photodynamic
therapy (PDT) of cancer. Cytotoxic action of photosensitisers
may involve oxidative damage to different cell constituents,
including depletion of the pool of cell antioxidants (free and
protein-bound thiols, ascorbic acid, a-tocopherol, etc.)
(Buettner, 1984, Shopova and Gantchev, 1990, Gantchev
and van Lier, 1995). Metallo-phthalocyanines (MePc)
constitute a class of dyes proposed as second-generation
photodynamic agents to supplant Photofrin, a mixture of
porphyrin derivatives, currently used in the clinical treatment
of various malignancies. Highly water-soluble phthalocya-
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nines, such as di- through tetrasulphonated derivatives
(MePcS2 4) partially localise in cytoplasm and photosensitise
intracellular generation of hydroxyl and organic free radicals
(Gantchev et al., 1994b). Among different effects of
photosensitised cell damage, tetrasulphonated Al- and
ZnPcS4 have been shown to weaken cell viability by
inactivation of catalase (Gantchev and van Lier, 1995) and
inflicting damage to DNA (Hunting et al., 1987; Gantchev et
al., 1994c). We have also shown that these phthalocyanines
can initiate oxidative transformations of VP-16 in solution
via photosensitised generation of VP-16 phenoxyl radical
(Gantchev et al., 1994a).
In view ofthe above properties ofphthalocyanines and the
interrelation between the rate of VP-16 oxidative transforma-
tion, its cytotoxicity, and the activity of intracellular
antioxidant systems, we hypothesised that PDT, in conjunc-
tion with etoposide, could result in enhanced cytotoxicity.
Analysis of different effects of combination therapy with VP-
16 and AlPcS4 photosensitisation against K562 chronic
myelogenous leukaemia cells is the subject of the present
work.
Materials and methods
Chemicals
Etoposide (VP-16) was purchased from Sigma (St Louis, MO,
USA). The compound was dissolved in dimethyl sulphoxide
(DMSO) at 5 mM, aliquoted and stored at -20°C. Further
dilutions were made in RPMI medium immediately before
use. Although the final DMSO concentrations of 1-2% in
cell cultures were not toxic, all control groups received an
equivalent amount of DMSO. Aluminium tetrasulphonated
phthalocyanine (AlPcS4) was synthesised in our laboratory,
purified by high-performance liquid chromatography (HPLC)
and dialysis to homogeneity and dissolved in phosphate-
buffered saline (PBS) to yield a stock solution of 1.5-
2.0 mm, as measured spectrophotometrically (8695 nm =
2.5 x 104 M-' cm-' in dimethylformamide). All other chemi-
cals used were of the highest available purity.
Cell culture and drug treatments
Human chronic myelogenous leukaemia cells, K562 (ATCC
CCL 243), were grown in RPMI-1640 medium, supplemented
with glutamine, 10% fetal bovine serum (FBS), 50 ,ug ml-'
gentamycin and 10 mM Hepes. All experiments werePDT and otoposide interactions
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performed with exponentially growing (asynchronous) cells.
Usually 12-14 h before the experiment, the cells were seeded
in a complete RPMI medium (3:1 v/v parts fresh to
conditioned medium) at cell density of approximately
0.4 x 106 cells ml-'. On the next day the cell density was
adjusted by a small volume of fresh medium to give 0.5 x 106
cells ml-' and cells were exposed to drugs (VP-16 and AlPcS4
alone, or mixed). All experiments were performed in triplicate
flasks. In a typical protocol, after incubation with drugs, cells
were first washed once with PBS, and a second time with
RPMI (without FBS). After resuspending in a complete
RPMI medium (conditioned to fresh medium = 1: 3 v/v), cells
were exposed to broad spectrum red light (A> i580 nm;
I = 10 mW cm-2). Cell suspensions (12-15 ml) were exposed
to red light in ventilated (green-cap Falcon, 75 cm-2)
incubation flasks and were gently shaken during irradiation.
Cells were incubated at 5 x 105 cells ml-1, or diluted to 5 x 104
cells ml-' to obtain a longer exponential phase. Control
experiments performed on cells that were first photosensitised
in PBS and then resuspended in culture medium did not show
any significant difference in cell survival. Dark incubation
with AlPcS4 was not cytotoxic. Exposure to red light of cells
incubated with VP-16, in the absence of AlPcS4, did not
result in altered VP-16 toxicity.
Cytotoxicity assays and drug interaction analysis
Cell growth inhibition was monitored by means of dye
exclusion (staining with 0.4% Trypan blue) and/or by
Coulter counter measurements. Under our experimental
conditions, the doubling time of control cells was 22-24 h.
The growth suppression activity of drugs was compared by
estimation of the exponential rate constants using initial
portions of growth curves (e.g. 48-60 h after treatment).
Clonogenic assay was performed in a standard fashion by
plating cells in soft (0.33%) agar in 35 mm Petri dishes
(usually 300, 600 and 1200 cells per dish in triplicate).
To analyse the dose-effect relationships in combination
treatment of cells with VP-16 and AlPcS4 photosensitisation,
two algorithms were used. A simple estimate was performed
using the fractional product method (Veleriote and Liu, 1975).
This 'multiplicative' model predicts additivity, antagonism
and/or synergism of two drugs based on the comparison
between the individual drug effect on cell survival, fu
(expected) =(fu)I x (fu)2 and the experimentally obtained value
ofcell survival after combination treatment, (f),2. The symbol
(f0),2 stands for 'fraction unaffected' and is equal to 1-(f)L,2,
where fa ('fraction affected') refers to the fraction of cells
responding to various concentrations of the two drugs in
combination. By definition, (u)1,2 lower, equal to or larger
than fu (expected) determines the border lines of synergistic
(supra-additive), additive and antagonistic drug interactions
respectively. In a specially designed set ofexperiments, we also
performed a detailed analysis of drug interactions using the
median effect principle. Unlike other methods often used to
predict drug interactions in biological systems (usually
applicable only to mutually exclusive interactions), the
median effect principle may be used to analyse both mutually
exclusive and mutually non-exclusive interactions (Chou and
Talalay, 1983). We used the linearised median effect equation
in the form of log [(fu) -'-1] = m log (D) - m log (Din), where
'm' is the Hill-type coefficient determining the sigmoidality of
the dose-effect curve; 'D' is drug(s) dose; and Dm =IC50 is the
dose required to produce the median effect. The combination
index (CI) was calculated at fa levels of 0.1 intervals, as
described by Chou and Talalay (1983). According to this
algorithm, CI values <1.0 indicate synergism; CI > 1.0,
antagonism; and CI approximately 1.0, additivity.
Flow cytometric cell cycle analysis
After given time periods following drug removal, cells were
washed and resuspended in 200 PBS containing 5.5 mM
glucose and 1 mM EDTA. While vortexing, 1 ml ofcold 70%
ethanol was added and cells were incubated at 4°C for
30 min. Thereafter, the cells were transferred to PBS-
glucose-EDTA buffer containing 0.5% Tween-20 and
incubated for 1 h at 4°C to rehydrate. Following a brief
exposure to RNAase, DNA was stained with 50 pg ml-'
propidium iodide. Before cytoflow analysis, cells were filtered
through nylon mesh to avoid clumps. The readings were
performed on a Hewlett-Packard computer-controlled Becton
Dickinson FACScan instrument. DNA chromatograms were
analysed by the SOBR software supplied by the manufac-
turer. In cases in which high levels ofcell debris were present,
appropriate gate cut-off settings were used.
Analysis of internucleosomal DNA fragmentation
The integrity of DNA from drug-treated and control cells
was assessed by agarose electrophoresis. After removal of
culture medium at different post-treatment times, cells
(0.5 2 x 106) were resuspended in 150 pl PBS-glucose-
EDTA buffer and transferred to Eppendorf microfuge tubes.
Immediately after that, 0.5 ml of lysis buffer [0.8% sodium
dodecyl sulphate (SDS) and 100 mM EDTA in 50 mM Tris-
HCI, pH=7.4] was added and cells were incubated at room
temperature for 20 min. After addition of 125 pl of 5 M
sodium chloride to each tube, samples were gently mixed and
left overnight at 4°C. On the next day, samples were
microcentrifuged at 12 000 xg for 30 min at 4°C and the
pellets were carefully removed and discarded. Supernatants
were further incubated with 0.45 mg ml-' proteinase K for
2 h at 50°C. After addition of 50 p1 of 5 M sodium chloride
and 1 ml isopropanol, samples were left for 1 h at -20°C
and microfuged. The pellet was washed with 70% ethanol
and dried under vacuum. Resuspended in 20 pl TE buffer,
pellets were incubated with 0.8 mg ml-' RNAase A at 37°C
for 3 h. After mixing with 4 p1 of 6 x loading buffer (TE/
bromophenol/glycerol), samples were transferred onto 1.2%
agarose gel and electrophoresed at 40 V for 4 h. Gels were
stained for 40 min with 10 ng ml-' ethidium bromide,
destained for 30-60 min in distilled water and photo-
graphed under UV light. Series of experiments were
performed to selected post-treatment time periods and
number of cells required to give early and easily detectable
DNA fragmentation in combination with selected multiple
drug dose equivalents to reveal drug interaction.
Results
Cell growth and loss of clonogenicity
To determine the toxicity range of individual drugs and their
combination effects, several parameters were examined:
incubation times of cells with drugs, drug concentrations
and the applied light dose for AlPcS4 activation. The cellular
response to drug treatment was followed by monitoring the
growth rate and cell clonogenic activity. Growth curves
shown in Figure 1 exemplify the evolution of immediate drug
toxicity with respect to drug incubation time, concentrations
and light dose. For individual drugs and their combinations,
growth curves show a proliferation lag period, followed either
by predominant cell regrowth or cell death. At low levels of
drug treatment (Figure la and b), and during the initial
proliferation lag-times (e.g. at post-treatment times shorter
than 24 h), the number of dead cells did not exceed 5-8% of
the total, but cell cycle progression was largely inhibited (see
below). Figure 2 demonstrates the effect of etoposide
concentration on clonogenic activity of K562 cells, either
when the drug was applied alone or in combination with
AlPcS4 photosensitisation. Under the employed incubation
conditions of cells with VP-16 (20-60 min), the ICso
concentration of the drug, as determined from cloning
experiments, was in the range from 15 to 6 pM, and was
markedly decreased after combined treatment (Figure 2). The
ICso ofAlPcS4 varied with preirradiation incubation time and
light dose (D), and, for example, after 4 h preincubation was
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Figure 1 Growth of K562 cells incubated for different times with VP-16 (0); AlPcS4 (A); or both (*) and exposed to red light. (a)
4 M AlPcS4 and 2gM VP-16 for 1 h, light dose (D)=7.2 Jcm-2; (b) 30,UM AlPcS4 for 5h and 7.5,UM VP-16 for 1 h, D=6 Jcm-2;
(c) 20/M AlPcS4 for 5h and IOjUM VP-16 for lh, D=9 Jcm-2; and (d) 40gM AlPcS4 for 5h and 30JM VP-16 for 2h,
D=9 JCm-2. Control cells (0). Incubation time starts after drug removal and light exposure. Averaged data from triplicate
experiments.
about 20 jgM (D =9 J cm-2), and increased when cells were
exposed to photosensitiser for a shorter time (e.g. 30-35 guM
at 2 h). The simple 'multiplicative' model and data from
cloning experiments (e.g. shown in Figure 2) largely predict
supra-additive (synergistic) combined toxicity [i.e. (fu)l,2<fu
(expected) =(f), x (Ju2, Materials and methods]. A complete
analysis of drug interaction, however, was performed using
the median effect principle, and is described below.
Cell cycle arrest
It has been shown previously that continuous exposure to
low concentrations of VP-16 allows cells of different origin to
traverse the cell cycle until a predominant number of them
are blocked with the DNA content of G2 cells, but cannot
progress to the mitotic stage (Krishan et al., 1975). In the
present study, the cells were incubated with VP-16 for given
time periods, and, thereafter, the drug was removed. Under
conditions of low drug load (,<IC50), VP-16 induced transient
G2/M arrest of K562 cells (Figure 3). Cell size analysis
performed by means of Coulter counter measurements
showed a parallel and transient increase in cell volume,
obviously associated with arrest in G2-phase. Higher doses
and longer exposures to the drug, however, resulted in S- and
mixed S/G2-phase arrest (not shown). It is noteworthy that in
this case, and after longer post-treatment incubation times
CD
m 0.1
c
0
II 0.01
n nni u.uu -
0 5 10
VP-16 (gM)
15
Figure 2 Clonogenic survival after exposure of K562 cells to
different concentrations of VP-16 for 1 h (A\); and after
combination treatment when cells were preincubated with 4 LM
AlPcS4 for 20 h (0); or with 20gM AlPcS4 for 4h (0). Light dose
in both cases, (D) = 7.2 Jcm-2. Averaged data from triplicate
experiments.
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Figure 3 Effects after exposure to VP-16 and AlPcS4 on cell cycle distribution of K562 cells. (lb) DNA chromatograms obtained
from cells 26h after treatment with 20 gM AlPcS4 for 5 h; (lc) 10gM VP-16 for 1 h; and (ld) combination of lb and lc. Light dose
(D) =9Jcm-2. (2b) Chromatograms obtained 20h after cell treatment with 4pM AlPcS4 for 1 h; (2c) 2pM VP-16 for 1 h; and (2d)
combination of 2b and 2c. Light dose 7.2 J cm 2. la and 2a show the chromatograms of control cells.
(>24 h), cell cycle analysis was more complicated owing to
the presence of high amounts of dead cells and a cell
population with quadraploid DNA content. In contrast,
AlPcS4 photosensitisation under a wide range of light doses
and preillumination incubation times (2-24 h), induced only
G2/M arrest. When cells were treated with doses around the
IC50 values of both drugs, the maximum number of G2/M-
arrested cells was reached after 15-20 h post-treatment
incubation and did not exceed a value of approximately
60% of the total (Figure 4a). The cell accumulation in G2/M
was accompanied by a depletion, mainly of S-phase
population, with very little variation in the GI-phase
content. During combined treatment, the cells were also
arrested in G2/M (Figure 3). The extent of cell response after
combined treatment varied and depended on the individual
drug effect. Thus, in conditions when individual drugs were
relatively more toxic (e.g. at doses approximately equal to the
IC50, see also Figure lb) and the maximum fraction of cells
arrested by individual drug treatment was close to 60%, there
was no significant increase in the G2/M population after
combined treatment. However, under these conditions, the
maximum number of G2/M-arrested cells after combined
treatment was reached at later times and the total
proliferation block lasted longer (Figure 4a). It is note-
worthy that in these conditions, during the growth lag period
and after that, the number of dead cells remained relatively
high, as also seen in DNA chromatograms exhibiting a higher
percentage of cells with abnormal DNA content (debris and,
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perhaps, apoptotic cells). In contrast, when the toxic effects
of individual drugs were low (growth curve shown in Figure
la), combined treatment induced a supra-additive (synergis-
tic) accumulation of cells in G2/M-phase, as also proved by
the 'multiplicative' model (Figure 4b). Synergistic increase of
the number of cells accumulated in G2/M-phase was reached
under various other conditions, but especially when the
toxicity of at least one of the drugs was kept low (Figure 4c).
Internucleosomal DNA degradation
K562 leukaemic cells are known to be relatively resistant to
VP-16-induced internucleosomal DNA fragmentation (apop-
tosis) (Dubrez et al., 1995). Thus, exposure of cells to VP-16
of concentrations around or higher than IC50 (5 gM and
10 gM for 1 or 2 h) did not reveal any significant DNA
fragmentation during post-treatment incubation times up to
36 h, as assessed by agarose gel electrophoresis (Figure 5,
lanes 4 and 5). DNA fragmentation was induced when cells
were treated with higher VP-16 concentrations (e.g. 5 x IC5o),
but the pattern was obscured even when DNA was isolated
from 2 x 106 or more cells (not shown). In contrast, AlPcS4
photosensitisation was a much more potent inducer of DNA
fragmentation (apoptosis). Internucleosomal DNA damage
was readily detected 4-6 h post treatment in DNA samples
isolated from 0.5-1.0 x 106 cells treated with drug dose
<IC50 (Figure 5, lane 3). This pattern was persistent and
progressively augmented during the next 48-72 h of post-
treatment incubation. Figure 5 also shows the results from a
typical experiment when cells were exposed to two drug
concentrations individually, or to their combination. Under
the specified conditions (see figure legend), no extensive DNA
laddering took place after treatment with either 5 gM AlPcS4
or 5 and 10 gM VP-16 alone (lanes 2, 4 and 5).
Internucleosomal cleavage, however, was well pronounced
in all samples when cells were subjected to combined
treatment. It is also noteworthy that in every case when
DNA internucleosomal fragments were easily seen, they were
superimposed on DNA smears. This is probably caused by
the occurrence of two parallel processes of DNA degradation
when cells were more heavily damaged: unprogrammed
(necrosis) and programmed (apoptosis) cell death. The
technique of agarose electrophoresis, as applied in this
study, does not permit a direct quantitative estimate of the
levels of internucleosomal damage induced by single and
combined treatment. From the selected drug doses and the
results shown in Figure 5, however, it is evident that
simultaneous employment of VP-16 with photodynamic
treatment induces supra-additive increase of DNA fragmenta-
tion.
Median effect - combination index analysis
The results shown in previous sections indicate that drug
combination treatment in most experimental conditions is
supra-additive (synergistic). To evaluate modes of drug
interactions, we designed experiments suitable for applica-
tion of combination index analysis. This analysis is based on
the median effect principle and is a statistical technique that
allows formal evaluation of the nature of interaction between
two cytotoxic agents. Cells were incubated with different
concentrations of drugs, but at constant molar ratio (VP-16/
AlPcS4 = 1/2). Before irradiation, the cells were exposed to
AlPcS4 for 1.5 h, followed by co-incubation with VP-16 for
0.5 h. Thereafter, the cells were washed and irradiated
(D = 7.2 J cm-2). Drug toxicity was assessed by their effect
on growth rate and clonogenicity. Figure 6 demonstrates
that, under these conditions, the AlPcS4 phototoxicity was
low, as estimated by both growth rate inhibition and loss of
clonogenicity. However, growth rate assessment of VP-16
toxicity underestimates the reproductive toxicity of the drug
(Figure 6). The median effect plots derived from cloning
experiments and linear regression data fit are shown in Figure
7. The dose-effect relationships of the individual drugs are
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Figure 4 Time-course of the accumulation of cells in G2/M
phase after treatment with (a) 20pM AlPcS4 for 5h (A); 10 M
VP-16 for 1 h (-); and their combination (*). Control cells (0).
After treatment of cells with (b) 4pgM AlPcS4 for 1 h; 2pM VP-16
for 1 h; and their combination; (c) 4,UM AlPcS4 for 20h; 2 LM VP-
16 for 1 h; and their combination. Light doses: (a) D=9 Jcm-2,
and (b and c) D = 7.2 Jcm-2. Averaged data from triplicate
experiments.
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Figure 5 Internucleosomal DNA fragmentation in K562 cells 4h
after treatment with drugs. Lanes: (1) control; (2 and 3) individual
drug treatment with 5pgM and 10pM AlPcS4 for 4h; (4 and 5)
5 pm and 10pM VP-16 for 1 h; (6 and 7) combination treatments:
5pM AlPcS4 and 5pM or 10 M VP-16; (8 and 9) 10pM AlPcS4
and 5pM or 10M VP-16. Lane 10, marker DNA (1, 2 and 3kb
fragments). Photosensitisation light dose, (D) =7.2 Jcm-2. DNA
was isolated from 0.5 x 106 cells in each case.
strictly linear (r>0.999, lines 1 and 2), while the plot
obtained for the mixture of the two drugs tends to concave
upward (r= 0.99) and intersects the plot of the more active
drug (Figure 7, line 3). It is, therefore, apparent that the
combined drug action is synergistic. This was further
confirmed by calculating the combination index values (CI)
for a wide range offa ('fraction affected', Figure 8). Since the
plots for the individual drugs are almost parallel (lines 1 and
2 in Figure 7), and the plot for the combined treatment (line
3) intersects the plot of the more active drug, it is likely that
the two drugs interact as mutually non-exclusive. The
combination index was calculated assuming both possibili-
ties, mutually exclusive and non-exclusive interactions. The
plots shown in Figure 8 indicate that these two models
predict synergistic toxicity (CI < 1) under conditions in which
combined treatment results in fa>0.10 or fa >0. 15 respec-
tively. For a comparison, CI values obtained from growth
inhibition data were also calculated and included in Figure 8.
It can be seen that synergism in the latter case is somewhat
overestimated, probably due to the underestimation of VP-16
toxicity by this criterion.
Discussion
We have investigated the effects of individual toxicity of
etoposide (VP-16) and photodynamic treatment with AlPcS4,
as well as the efficacy of drug combination against K562
human leukaemic cells. Similarly, in our previous studies with
Namalva Burkitt's lymphoma cells (Gantchev et al., 1994b,
photosensitisation of K562 cells results in division block and,
depending on the extent of the treatment, is followed either
by cell regrowth or by predominant cell death. Unlike
photosensitisation with Photofrin, which induces S-phase
cell cycle arrest (Gantchev et al., 1994d), in the present study
we show that AlPcS4 photosensitisation arrests cells in G2/M-
phase. Under the conditions of relatively mild photodynamic
treatment employed, no evidence for immediate membrane
disintegration was found. In contrast, most of the toxic
effects were delayed and emerged as a function of post-
treatment incubation time, as seen, for example, by the time
course of the accumulation of G2/M-arrested cells and
internucleosomal DNA cleavage. Similar cell growth inhibi-
tion effects were observed after short (0.5-2 h) exposure of
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Figure 6 Cell survival (loss of clonogenicity, open symbols) and
growth rate inhibition (closed symbols) after photosensitisation
with AlPcS4 (A, A), incubation with VP-16 (0, 0) and
combination treatment (O, *). Cells were incubated with
various concentrations of AlPcS4 for 2h and with VP-16 for
30min. Drug concentration ratio VP-16/AlPcS4= 1/2. Light dose,
(D) =7.2 Jcm-2. Combination treatment curves are plotted as a
function of VP-16 concentration. Growth inhibition was
estimated by comparison of growth rate constants. Averaged
data from triplicate samples.
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Figure 7 (1) Median-effect plots for the cytotoxicity of VP-16;
(2) AlPcS4 and (3) their combination. Experimental data from
clonogenic survival (Figure 6).
n ni
aIPDT and otoposide interactions
$0 TG Gantchev et al
1576
shown that DNA fragmentation evolves within minutes after
treatment, in contrast to the slower accumulation of
apoptotic cells after AlPcS4 and/or VP-16 treatment. Water-
soluble phthalocyanines, such as AlPcS4, have been
implicated in the induction of DNA strand breaks, DNA-
protein cross-links (Hunting et al., 1987; Gantchev et al.,
1994c), and impairment of cell organelles, including
peroxisomes (Peng et al., 1991). All these oxidative processes
may account for AlPcS4 cytotoxicity and represent primary
events in AlPcS4 - PDT-mediated internucleosomal DNA
cleavage.
hle cytostatic/cytotoxic action Of VP-1 iS generally
believed to involve formation of DNA-protein cross-links
and breaks. However, it is likely that drug toxicity is not
limited to topoisomerase II (topo II) poisoning only. Thus, a
recent study argued on the lack of correlation between the
level of DNA-protein cross-links and cytotoxicity in several
leukaemic cell lines (Dubrez et al., 1995). Previously, other
studies have also indicated that the interaction of VP-16 with
topo II and cytotoxicity of the drug can be uncoupled, e.g.
drug interaction with topo II might be not intrinsically
cytotoxic, and therefore it has been suggested that VP-16
cytotoxic action might involve one, or more, intervening
metabolic steps (Kaufmann, 1989; Walker et al., 1991).
Oxidoreductive transformations of VP-16 induced by a
variety of intracellular enzymatic systems have been shown
to constitute a pathway for modulation of drug activity (van
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for [VP-16]/[AlPcS4] = 1/2, data from clonogen
drugs (M, 0), or growth inhibition (Ej, 0),
mutually exclusive (0, *) and mutually non-ex
*).
K562 cells to VP-16. The cytotoxicity
however, evolved faster compared with VI
lar, PDT-induced growth and clonogenic
oped at similar rates, while VP-16 displaye
growth suppression, compared with the
clonogenic inhibition (Figure 6). When ap
16 did not induce any significant internu
degradation (apoptosis). Apoptotic cell dez
response to AlPcS4-PDT and was augmente
drug treatment (Figure 5). Synergistic (
combined drug treatment was attained
conditions, as clearly demonstrated by g
rates (Figure la and d), loss of clonogenici
accumulation of cells in G2/M cell cycle pha
c). In particular, synergism (supra-additiv
arrest took place when the fraction of G2/M
single drug treatment did not exceed a v
mately 60%. Quantitatively, this value co
normal S-phase fraction of exponentially gr
and implies that drug treatment exclusi'
during the stage of DNA synthesis. Aftei
treatment and during the accumulation o
phase, a progressive increase of DNA
fragmentation was observed. It is, there
when cells are more extensively damaged b
treatment, G2/M-arrested cells tend to fall
cycle and die (eventually by apoptosis).
mechanisms that are involved in AlP
apoptosis were not addressed in this stuc
suggest that they do not encompass the phos
A2, signalling pathway shown to operat
sensitisation with cytoplasmic membrane-l
stituted) AlPc (Agarwal et al., 1993). In th
primary target is the cytoplasmic membrane
Maanen et at., 1987; Mans et al., 1990; Haim et al., 1991).
Furthermore, the intermediate species from VP-16 metabo-
lism: VP-16 phenoxyl and semi-quinone radicals, and one of 0.8 1.0 the final products of drug demethylation (VP-16 ortho-
quinone) have been implicated as important cytotoxic agents
action affected (fa) (Mans et al., 1991, 1992; Ritov et al., 1995). It is, however,
kic toxicity of the noteworthy that the intracellular accumulation of these
as calculated for products depends strongly on the presence of cellular
Kclusive drugs (Fi, antioxidants (e.g. reduced ascorbate and thiols) (Gantchev
et al., 1994a; Kagan et al., 1995).
The combination index analysis of AlPcS4 photosensitisa-
tion and VP-16 treatment as performed in the present work
largely predicts synergistic toxicity of the two drugs. The
of AlPcS4-PDT, experiments throughout this study were performed so that
P-16. In particu- effects, such as cell synchronisation, were avoided and cannot
inhibition devel- account for the observed synergy. Moreover, the median
J a lower level of effect plot of combined toxicity (Figure 7) suggests that the
more effective drugs are likely to interact as mutually non-exclusive. Non-
)plied alone, VP- exclusivity of drug interaction would imply that AlPcS4 and
.icleosomal DNA VP-16 share a common intracellular target and/or interact
ath was an early chemically. It is not known if AlPcS4 photosensitisation can
d after combined directly interfere with the topo II/DNA breakage-reunion
cell response to process, but it is recognised that photosensitisation (Hunting
under various et al., 1987; Gantchev et al., 1994c) and VP-16 metabolites
,rowth inhibition (van Maanen et al., 1988b; Mans et al., 1990, 1991; Sinha et
ty (Figure 2) and al., 1990) can instantly induce damage to DNA. Therefore,
se (Figure 3b and based on the assumption that metabolic oxidoreductive
ity) in cell cycle transformations of VP-16 are important for its cytotoxic
I cells arrested by action, we suggest that photosensitisation-induced depletion
ralue of approxi- of intracellular reductants facilitates VP-16 metabolism,
trresponds to the probably on the level of VP-16 phenoxyl free radical
-owing K562 cells transformations. Generation of the VP-16 phenoxyl radical
vely affects cells is the primary step in the enzymatic metabolism of the drug
r combined drug and the interactions of the phenoxyl radical with cell
tf cells in G2/M- antioxidants prevents etoposide from further transforma-
internucleosomal tions and results in recovery of its original form. Also, the
fore, likely that VP-16 phenoxyl radical may itself initiate oxidative cell
ty combined drug damage (Ritov et al., 1995). A parallel drug interaction
out from the cell mechanism may involve direct AlPcS4-mediated photo-
The molecular oxidation of VP-16 to yield the phenoxyl radical (Gantchev
cS4-PDT-induced et al., 1994a). Complete elucidation of the role of these
ly. However, we different pathways and the involvement of additional
pholipases C and processes that may explain the observed synergistic drug
;e during photo- toxicity will require further experimental work. It is relevant
ocalising (unsub- to note that a recent study showed synergism in cells
e latter case, the subjected to gamma radiation and etoposide treatment
, and it has been (Haddock et al., 1995). Since the oxidative processes induced
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by PDT and radiotherapy are similar, it is possible that the
synergistic interactions with etoposide are based on the same
mechanisms. Although the presented results only involve in
vitro synergy between photodynamic treatment and etoposide
toxicity, our findings may provide alternative perspectives for
clinical PDT and etoposide applications.
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